NeOnc Technologies Holdings, Inc. (NTHI)
NGM · Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration for the treatment of primary brain cancers, such as meningioma, high grade gliomas, glioblastoma, and secondary brain cancers. The company was formerly known as NAS-ONC, Inc. and changed its name to NeOnc Technologies Holdings, Inc. in 2009. The company was incorporated in 2005 and is headquartered in Calabasas, California.
Peers in Biotechnology
All in industry →Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.
Recent press releases
April 2026
NeOnc Files $75M ATM Offering to Pay Taxes, Fund Trials
Here's a clear, structured summary of NeOnc Technologies' SEC filing (Form 424B5): # 🧾 What This Document Is This is a **Prospectus Supplement** for a **$75,000,000 "at-the-market" (ATM) offering** of NeOnc's common stock. It updates and adds details to a base prospectus filed earlier. NeOnc can s
SEC filings
All filings →Insider trades
All insider trades →NeOnc Technologies Holdings, Inc. has no reported insider trades in the last 90 days.